-
FDA Narrows Use of PD-1 Drugs in GI Cancers
FDA
The FDA has restricted Merck’s Keytruda and BMS’s Opdivo for use only in PD-L1-positive gastric, GEJ, and esophageal cancers, citing limited benefit in PD-L1-negative patients based on recent trial data.
-
PD-(L)1 Resistance Hope
PD-1
Explore how LRRC15+ CAFs contribute to PD-1 resistance, the role of LRRC15 in tumor immunity, and emerging therapies targeting LRRC15 and PD-1 to improve cancer immunotherapy outcomes.
桦南县|
香格里拉县|
甘谷县|
繁昌县|
富锦市|
泾川县|
沾化县|
阿合奇县|
彝良县|
廉江市|
杭锦旗|
馆陶县|
衡阳市|
昌吉市|
乐平市|
青海省|
江山市|
盐边县|
大名县|
文成县|
甘孜县|
贵德县|
阳城县|
武平县|
双峰县|
若尔盖县|
新河县|
德清县|
山东省|
香格里拉县|
浦东新区|
石门县|
北流市|
龙山县|
金沙县|
宜君县|
湘西|
丰宁|
台中县|
亚东县|
大邑县|